Baxter’s Phoxillum Renal Replacement Solutions obtains FDA approval
Pharmaceutical Technology
http://www.pharmaceutical-technology.com/news/newsbaxter-phoxillum-renal-replacement-4493678?WT.mc_id=DN_News
Baxter International has received approval from US Food and Drug Administration (FDA) for its Phoxillum Renal Replacement Solutions (BK4/2.5 and B22K4/0) to use as replacement solutions in continuous renal replacement therapy (CRRT).
The therapy aims to correct electrolyte and acid-base imbalances.
In addition, Phoxillum can be used in case of drug poisoning when CRRT is used to remove dialysable substances.
Baxter vice-president and renal therapeutic area lead Bruce Culleto said: "The approval of Phoxillum allows us to offer healthcare providers additional options in managing critically ill acute kidney injury patients treated with CRRT.
